{"url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152775/", "query": "oral chelation heart disease", "contents": "<?xml version=\"1.0\" encoding=\"utf-8\"?>\n<!DOCTYPE html PUBLIC \"-//W3C//DTD XHTML 1.0 Transitional//EN\" \"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd\">\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\">\n    \n    <head><meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n        <!-- AppResources meta begin -->\n        <script type=\"text/javascript\">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name=\"paf_template\" content=\"\" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name=\"ncbi_db\" content=\"pmc\" /><meta name=\"ncbi_pdid\" content=\"article\" /><meta name=\"ncbi_acc\" content=\"\" /><meta name=\"ncbi_domain\" content=\"nihpa\" /><meta name=\"ncbi_report\" content=\"record\" /><meta name=\"ncbi_type\" content=\"fulltext\" /><meta name=\"ncbi_objectid\" content=\"\" /><meta name=\"ncbi_pcid\" content=\"/articles/PMC4152775/\" /><meta name=\"ncbi_app\" content=\"pmc\" />\n        <!-- Logger end -->\n        \n        <title>Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel=\"stylesheet\" href=\"/core/jig/1.14.8/css/jig.min.css\" /><script type=\"text/javascript\" src=\"/core/jig/1.14.8/js/jig.min.js\"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name=\"robots\" content=\"INDEX,NOFOLLOW,NOARCHIVE\" /><link rel=\"canonical\" href=\"/pmc/articles/PMC4152775/\" /><link rel=\"schema.DC\" href=\"http://purl.org/DC/elements/1.0/\" /><meta name=\"citation_journal_title\" content=\"Trends in cardiovascular medicine\" /><meta name=\"citation_title\" content=\"Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients\" /><meta name=\"citation_authors\" content=\"Julio G. Peguero, Ivan Arenas, Gervasio A. Lamas\" /><meta name=\"citation_date\" content=\"August 2014\" /><meta name=\"citation_issue\" content=\"6\" /><meta name=\"citation_volume\" content=\"24\" /><meta name=\"citation_firstpage\" content=\"232\" /><meta name=\"citation_doi\" content=\"10.1016/j.tcm.2014.06.002\" /><meta name=\"citation_pmid\" content=\"25106084\" /><meta name=\"DC.Title\" content=\"Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients\" /><meta name=\"DC.Type\" content=\"Text\" /><meta name=\"DC.Publisher\" content=\"NIH Public Access\" /><meta name=\"DC.Contributor\" content=\"Julio G. Peguero\" /><meta name=\"DC.Contributor\" content=\"Ivan Arenas\" /><meta name=\"DC.Contributor\" content=\"Gervasio A. Lamas\" /><meta name=\"DC.Date\" content=\"2014 Aug\" /><meta name=\"DC.Identifier\" content=\"10.1016/j.tcm.2014.06.002\" /><meta name=\"DC.Language\" content=\"en\" /><meta property=\"og:title\" content=\"Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients\" /><meta property=\"og:type\" content=\"article\" /><meta property=\"og:url\" content=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4152775/\" /><meta property=\"og:site_name\" content=\"PubMed Central (PMC)\" /><meta property=\"og:image\" content=\"https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png\" /><meta name=\"twitter:card\" content=\"summary\" /><meta name=\"twitter:site\" content=\"@ncbi\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc.min.css\" type=\"text/css\" /><link rel=\"stylesheet\" href=\"/corehtml/pmc/css/3.6/pmc_extras_prnt.min.css\" type=\"text/css\" media=\"print\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/js/common.min.js\">//</script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/NcbiTagServer.min.js\">//</script><meta name=\"citationexporter\" content=\"backend:'/pmc/utils/ctxp/'\" /><script type=\"text/javascript\" src=\"/corehtml/pmc/ctxp/jquery.citationexporter.js\">//</script><link rel=\"stylesheet\" href=\"/corehtml/pmc/ctxp/citationexporter.css\" type=\"text/css\" /><script type=\"text/javascript\" src=\"/core/mathjax/2.6.1/MathJax.js?config=/corehtml/pmc/js/mathjax-config-classic.3.4.js\"></script><script type=\"text/javascript\" src=\"/corehtml/pmc/js/large-obj-scrollbars.min.js\"></script><script type=\"text/javascript\">window.name=\"mainwindow\";</script><style type=\"text/css\">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-hhspa.gif);background-size: auto, contain}</style><style type=\"text/css\">.print-view{display:block}</style><style type=\"text/css\">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name=\"cited_in_systematic_reviews\" content=\"\" /><link rel=\"alternate\" type=\"application/epub+zip\" href=\"/pmc/articles/PMC4152775/epub/\" /><link rel=\"alternate\" type=\"application/pdf\" href=\"/pmc/articles/PMC4152775/pdf/nihms619516.pdf\" />\n\n        <!-- Page meta end -->\n    <link rel=\"shortcut icon\" href=\"//www.ncbi.nlm.nih.gov/favicon.ico\" /><meta name=\"ncbi_phid\" content=\"F4FC52E181E984D10000000000800074\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4120508/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4052581/9685/3549676/3609192/3609193/3609213/3395586/3855312.css\" /><link type=\"text/css\" rel=\"stylesheet\" href=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/css/3411343/3882866/3929378.css\" media=\"print\" /></head>\n    <body class=\"article\">\n        <div class=\"grid\">\n            <div class=\"col twelve_col nomargin shadow\">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class=\"sysmessages\">\n                    <noscript>\n\t<p class=\"nojs\">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href=\"/guide/browsers/#enablejs\" title=\"Learn how to enable JavaScript\" target=\"_blank\">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class=\"wrap\">\n                    <div class=\"page\">\n                        <div class=\"top\">\n                            <div class=\"universal_header\" id=\"universal_header\"><ul class=\"inline_list jig-ncbimenu ui-ncbimenu resources_list\" id=\"navcontent\"><li class=\"ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt\"><a class=\"ui-ncbimenu-link-first\" href=\"/\" role=\"banner\" title=\"NCBI Home\" id=\"ncbihome\" accesskey=\"1\"><span class=\"offscreen_noflow\">NCBI</span><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/28977\" class=\"ncbi_logo\" title=\"NCBI\" alt=\"NCBI Logo\" /></a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#maincontent\" title=\"Skip to the content\" tabindex=\"0\" accesskey=\"3\">Skip to main\n                        content</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"#navcontent\" title=\"Skip to the navigation\" tabindex=\"0\" accesskey=\"4\">Skip to\n                        navigation</a></li><li id=\"resource-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#resources\">Resources</a></li><li id=\"all-howtos-menu\" class=\"topmenu ui-helper-reset ui-ncbimenu-item-first\"><a class=\"ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown\" href=\"/static/header_footer_ajax/submenu/#howto\">How To</a></li><li class=\"offscreen_noflow ui-ncbimenu-item-skip access\"><a href=\"/guide/browsers/#accesskeys\" title=\"About My NCBI Accesskeys\" tabindex=\"0\" accesskey=\"0\">About NCBI Accesskeys</a></li></ul><div class=\"myncbi\"><span id=\"myncbiusername\" style=\"display:none\"><a href=\"/account/settings/\" id=\"mnu\" title=\"Edit account settings\"></a></span><a accesskey=\"2\" href=\"/myncbi/\" id=\"myncbi\" style=\"display:none\">My NCBI</a><a href=\"/account/\" id=\"sign_in\">Sign in to NCBI</a><a href=\"/account/signout/\" id=\"sign_out\" style=\"display:none\">Sign Out</a></div></div>\n                            <div class=\"header\">\n    <div class=\"res_logo\">\n  <h1 class=\"img_logo\"><a href=\"/pmc/\" class=\"pmc_logo offscreen\">PMC</a></h1>\n  <div class=\"NLMLogo\">\n    <a href=\"https://www.nlm.nih.gov/\" title=\"US National Library of Medicine\">US National Library of Medicine</a>\n    <br />\n    <a href=\"https://www.nih.gov/\" title=\"National Institutes of Health\">National Institutes of Health</a>\n  </div>\n</div>\n    <div class=\"search\"><form method=\"get\" action=\"/pmc/\"><div class=\"search_form\"><label for=\"database\" class=\"offscreen_noflow\">Search database</label><select id=\"database\"><optgroup label=\"Recent\"><option value=\"pmc\" selected=\"selected\" class=\"last\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option></optgroup><optgroup label=\"All\"><option value=\"gquery\">All Databases</option><option value=\"assembly\">Assembly</option><option value=\"bioproject\">BioProject</option><option value=\"biosample\">BioSample</option><option value=\"biosystems\">BioSystems</option><option value=\"books\">Books</option><option value=\"clinvar\">ClinVar</option><option value=\"clone\">Clone</option><option value=\"cdd\">Conserved Domains</option><option value=\"gap\">dbGaP</option><option value=\"dbvar\">dbVar</option><option value=\"nucest\">EST</option><option value=\"gene\">Gene</option><option value=\"genome\">Genome</option><option value=\"gds\">GEO DataSets</option><option value=\"geoprofiles\">GEO Profiles</option><option value=\"nucgss\">GSS</option><option value=\"gtr\">GTR</option><option value=\"homologene\">HomoloGene</option><option value=\"medgen\">MedGen</option><option value=\"mesh\">MeSH</option><option value=\"ncbisearch\">NCBI Web Site</option><option value=\"nlmcatalog\">NLM Catalog</option><option value=\"nuccore\">Nucleotide</option><option value=\"omim\">OMIM</option><option value=\"pmc\" data-ac_dict=\"pmc-search-autocomplete\">PMC</option><option value=\"popset\">PopSet</option><option value=\"probe\">Probe</option><option value=\"protein\">Protein</option><option value=\"proteinclusters\">Protein Clusters</option><option value=\"pcassay\">PubChem BioAssay</option><option value=\"pccompound\">PubChem Compound</option><option value=\"pcsubstance\">PubChem Substance</option><option value=\"pubmed\">PubMed</option><option value=\"pubmedhealth\">PubMed Health</option><option value=\"snp\">SNP</option><option value=\"sparcle\">Sparcle</option><option value=\"sra\">SRA</option><option value=\"structure\">Structure</option><option value=\"taxonomy\">Taxonomy</option><option value=\"toolkit\">ToolKit</option><option value=\"toolkitall\">ToolKitAll</option><option value=\"toolkitbook\">ToolKitBook</option><option value=\"toolkitbookgh\">ToolKitBookgh</option><option value=\"unigene\">UniGene</option></optgroup></select><div class=\"nowrap\"><label for=\"term\" class=\"offscreen_noflow\" accesskey=\"/\">Search term</label><div class=\"nowrap\"><input type=\"text\" name=\"term\" id=\"term\" title=\"Search PMC. Use up and down arrows to choose an item from the autocomplete.\" value=\"\" class=\"jig-ncbiclearbutton jig-ncbiautocomplete\" data-jigconfig=\"dictionary:'pmc-search-autocomplete',disableUrl:'NcbiSearchBarAutoComplCtrl'\" autocomplete=\"off\" data-sbconfig=\"ds:'no',pjs:'no',afs:'yes'\" /></div><button id=\"search\" type=\"submit\" class=\"button_search nowrap\" cmd=\"go\">Search</button></div></div></form><ul class=\"searchlinks inline_list\"><li>\n                        <a href=\"/pmc/advanced/\">Advanced</a>\n                    </li><li>\n                        <a href=\"/pmc/journals/\">Journal list</a>\n                    </li><li class=\"help\">\n                        <a target=\"_blank\" href=\"/books/NBK3825/\">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id=\"Page\" label=\"headcontent\"/>-->\n                            \n                        </div>\n                        <div class=\"content\">\n                            <!-- site messages -->\n                            <div class=\"container\">\n    <div id=\"maincontent\" class=\"content eight_col col\">\n        <div class=\"navlink-box\">\n            <ul class=\"page-breadcrumbs inline_list small\"><li class=\"journal-list\"><a href=\"/pmc/journals/\" class=\"navlink\">Journal List</a></li><li class=\"article-entrez-filter\"><a href=\"/pmc/?term=hhs%20author%20manuscript[filter]\" class=\"navlink\">HHS Author Manuscripts</a></li><li class=\"accid\">PMC4152775</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class=\"pmc-page-banner whole_rhythm\"><div><img src=\"/corehtml/pmc/pmcgifs/logo-hhspa.png\" alt=\"Logo of nihpa\" usemap=\"#logo-imagemap\" /><map id=\"logo-imagemap\" name=\"logo-imagemap\"><area shape=\"rect\" coords=\"0,57,255,75\" alt=\"About Author manuscripts\" title=\"About Author manuscripts\" href=\"https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html\" ref=\"https://www.ncbi.nlm.nih.gov/pmc/about/authorms.html\" /><area shape=\"rect\" coords=\"256,57,500,75\" alt=\"Submit a manuscript\" title=\"Submit a manuscript\" href=\"https://www.nihms.nih.gov/\" ref=\"reftype=publisher&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /><area shape=\"rect\" coords=\"0,0,499,74\" alt=\"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;\" title=\"HHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;\" href=\"https://www.ncbi.nlm.nih.gov/pmc/about/public-access/\" ref=\"reftype=publisher&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal\" target=\"pmc_ext\" /></map></div> </div>\n        \n        <!--component id='MainPortlet' label='search-reference'/-->\n        \n        <!-- Book content -->\n        <div class=\"\">\n            \n        \n            \n            <div class=\"hide-overflow article lit-style content pmc-wm slang-all page-box\"><!--main-content--><div class=\"jig-ncbiinpagenav\" data-jigconfig=\"smoothScroll: false, allHeadingLevels: ['h2'], headingExclude: ':hidden'\"><div class=\"fm-sec half_rhythm no_top_margin\"><div class=\"fm-citation half_rhythm no_top_margin clearfix\"><div class=\"small\"><div class=\"inline_block eight_col va_top\"><div><span id=\"pmcmata\">Trends Cardiovasc Med</span>. Author manuscript; available in PMC 2015 Aug 1.</div><div></div><div>Published in final edited form as:</div><div style=\"margin-left:1em\"><div class=\"fm-vol-iss-date\"><a href=\"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25106084\" target=\"pmc_ext\" ref=\"reftype=publisher&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal\"><span class=\"cit\">Trends Cardiovasc Med. 2014 Aug; 24(6): 232\u2013240. </span></a></div><span class=\"fm-vol-iss-date\">Published online 2014 Jun 12. </span> <span class=\"doi\">doi:\u00a0 <a href=\"//dx.doi.org/10.1016%2Fj.tcm.2014.06.002\" target=\"pmc_ext\" ref=\"reftype=other&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal\">10.1016/j.tcm.2014.06.002</a></span></div></div><div class=\"inline_block four_col va_top show-overflow align_right\"><div class=\"fm-citation-ids\"><div class=\"fm-citation-pmcid\"><span class=\"fm-citation-ids-label\">PMCID: </span><span>PMC4152775</span></div><div class=\"fm-citation-manuscriptid\"><span class=\"fm-citation-ids-label\">NIHMSID: </span><span>NIHMS619516</span></div></div></div></div></div><h1 class=\"content-title\">Chelation Therapy and Cardiovascular Disease: Connecting Scientific Silos to Benefit Cardiac Patients</h1><div class=\"half_rhythm\"><div class=\"contrib-group fm-author\"><a href=\"/pubmed/?term=Peguero%20JG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25106084\">Julio G. Peguero</a>, MD, <a href=\"/pubmed/?term=Arenas%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25106084\">Ivan Arenas</a>, MD, PhD, and  <a href=\"/pubmed/?term=Lamas%20GA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=25106084\">Gervasio A. Lamas</a>, MD</div></div><div class=\"fm-panel small half_rhythm\"><div class=\"fm-authors-info fm-panel hide half_rhythm\" id=\"id1026016_ai\" style=\"display:none\"><div class=\"fm-affl\" lang=\"en\">Columbia University Division of Cardiology at Mount Sinai Medical Center, Miami Beach, FL 33140</div><div id=\"FN1\">Address for Correspondence: Gervasio A. Lamas, MD, Columbia University Division of Cardiology at Mount Sinai Medical Center, 4300 Alton Road, Suite # 2070A, Miami Beach, FL 33140</div></div><div class=\"togglers\"><a href=\"#\" class=\"pmctoggle\" rid=\"id1026016_ai\">Author information <span>\u25ba</span></a> <a href=\"#\" class=\"pmctoggle\" rid=\"id1026016_cpl\">Copyright and License information <span>\u25ba</span></a></div><div class=\"fm-article-notes fm-panel half_rhythm\"></div><div class=\"fm-cpl-info fm-panel hide half_rhythm\" id=\"id1026016_cpl\" style=\"display:none\"><div class=\"fm-copyright half_rhythm\"><a href=\"/pmc/about/copyright/\">Copyright notice</a>  and <a href=\"/About/disclaimer.html\">Disclaimer</a></div><div><a href=\"#FN3\">Publisher's Disclaimer</a></div></div></div><div id=\"pmclinksbox\" class=\"links-box fm-panel whole_rhythm\"><div class=\"small\"><div>The publisher's final edited version of this article is available  at <a href=\"/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;retmode=ref&amp;cmd=prlinks&amp;id=25106084\" target=\"pmc_ext\" ref=\"reftype=publisher&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CArticle%7CRestricted%20Access&amp;rendering-type=normal\">Trends Cardiovasc Med</a></div><div>See other articles in PMC that <a href=\"/pmc/articles/PMC4152775/citedby/\">cite</a> the published article.</div></div></div></div><div class=\"sec\"></div><div id=\"S1\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"S1title\">Background</h2><div id=\"S2\" class=\"sec sec-first\"><h3>Evidence of xenobiotic metal toxicity</h3><p id=\"P1\" class=\"p p-first\">Metals play an important role in human biology. Iron is critical for oxygen transport in hemoglobin. Zinc is a critical part of the angiotensin converting enzyme metalloprotein. But there are many metals that have no beneficial role in human biology. These metals have been referred to as heavy metals, or toxic metals. The terms are imprecise because these definitions all relate either to specific chemical properties or atomic weight, or functional aspects in human biology. We will use the term xenobiotic metal to refer to those metals without any specific role in the human body.</p><p id=\"P2\">The epidemiologic evidence that many xenobiotic metals are toxic is robust. For example, arsenic, cadmium, lead, and mercury are ranked among the top 10 on the current Agency for Toxic Substances and Disease Registry Priority List of Hazardous Substances. Arsenic, lead, and mercury are ranked as the top 3 hazardous substances (<a href=\"#R1\" rid=\"R1\" class=\" bibr popnode\">1</a>).</p><p id=\"P3\" class=\"p p-last\">Within the cardiovascular system, xenobiotic metals have been linked to worsening hypertension, atherosclerosis, dyslipidemia, coronary artery disease and peripheral artery disease (PAD). We highlight below two metals, lead and cadmium, with demonstrated hazardous effects on human health that could at least partially explain the beneficial effects of chelation therapy. EDTA chelates both of these metals. We emphasize, however, that other mechanisms may be at play, and that extensive work will have to be carried out to fully understand the mechanism of benefit of the TACT infusions.</p></div><div id=\"S3\" class=\"sec\"><h3>Lead</h3><p id=\"P4\" class=\"p p-first\">Lead is a toxic environmental pollutant, considered one of the most abundant xenobiotic metals. The main sources of exposure are contaminated water, air, food or soil. Lead, is often acquired through occupational exposure, soldered joints in water pipes, airborne emissions, lead-containing food products and the well-known lead-based paints (<a href=\"#R2\" rid=\"R2\" class=\" bibr popnode\">2</a>).</p><p id=\"P5\">Once absorbed, more than 90% of lead is accumulated in the bone. The lead stored in bone can remain for many years and be released years later into the blood stream, long after exposure. Blood lead levels are the usual method of testing for toxicity, but they only reflect recent exposure. In fact, the levels of blood lead have been falling steadily since leaded gasoline for road-driven vehicles was eliminated. However, environmental exposure continues, and the cardiovascular consequences are not restricted to high, recent exposure levels.</p><p id=\"P6\">Epidemiological studies have found associations between elevated lead levels and the prevalence of cardiovascular disease (<a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590988\">3</a>&#x02013;<a href=\"#R9\" rid=\"R9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591028\">9</a>). In 4 large population-based studies published from the National Health and Nutrition Examination Survey (NHANES), higher blood lead levels were found to be associated with a more than 25% increased risk of all cause mortality, 55% increased risk of cardiovascular mortality and a 2 fold higher risk of mortality from stroke (<a href=\"#R5\" rid=\"R5\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591019\">5</a>&#x02013;<a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590987\">8</a>). Other important associations of high blood lead levels include peripheral artery disease, dyslipidemia and hypertension (<a href=\"#R3\" rid=\"R3\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591022\">3</a>,<a href=\"#R4\" rid=\"R4\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590999\">4</a>,<a href=\"#R6\" rid=\"R6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590998\">6</a>,<a href=\"#R7\" rid=\"R7\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591010\">7</a>,<a href=\"#R9\" rid=\"R9\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590991\">9</a>). These complications have been associated with the upper limit of what is considered safe blood lead levels for adults (<a href=\"#R5\" rid=\"R5\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591024\">5</a>), suggesting that there may be no &#x0201c;safe&#x0201d; levels for this toxic substance.</p><p id=\"P7\" class=\"p p-last\">The mechanisms of lead toxicity are not fully understood. Lead may cause endothelial dysfunction by binding and inhibiting endothelial nitric oxide synthase and decreasing nitric oxide production (<a href=\"#R10\" rid=\"R10\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591008\">10</a>) Lead also creates reactive oxygen species (ROS) which damage cell structures including DNA and cell membranes. Lead can replace other metal cofactors during enzymatic reactions therefore altering or compromising the end product. In the mitochondria, lead can replace zinc cofactor halting the formation of hemoglobin and accumulating toxic levels of aminolevulinic acid.</p></div><div id=\"S4\" class=\"sec\"><h3>Cadmium</h3><p id=\"P8\" class=\"p p-first\">Cadmium is an extremely toxic metal that does not have any biological role in humans. Rechargeable batteries account for the majority of cadmium industrial use presently. And their safe disposal remains a challenge. Some plants, fruits and grains, can avidly absorb cadmium from the soil and/or water, creating another source for human exposure and toxicity (<a href=\"#R2\" rid=\"R2\" class=\" bibr popnode\">2</a>). Tobacco plants, for example, avidly take up cadmium in the leaf. Hence smoking is the most important single source of cadmium exposure in the general population (<a href=\"#R11\" rid=\"R11\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591027\">11</a>,<a href=\"#R12\" rid=\"R12\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591029\">12</a>).</p><p id=\"P9\">There is robust literature on the association of cadmium with cardiovascular disease (<a href=\"#R5\" rid=\"R5\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591020\">5</a>,<a href=\"#R6\" rid=\"R6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591025\">6</a>,<a href=\"#R8\" rid=\"R8\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591031\">8</a>,<a href=\"#R13\" rid=\"R13\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591002\">13</a>&#x02013;<a href=\"#R15\" rid=\"R15\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591013\">15</a>) For example, Tellez-Plaza et al recently reported a study of 3,348 patients with measurement of urinary cadmium. The patients were participants in the Strong Heart Study, a large cohort of the Native American population. Elevated levels or urinary cadmium were found to increase the incidence of all-cause, cardiovascular, and coronary heart disease mortality. These associations were found to be stronger in patients with known diabetes (<a href=\"#R14\" rid=\"R14\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591030\">14</a>), a finding that presaged the TACT diabetes results. A systematic review of 12 studies of cadmium exposure and clinical cardiovascular disease reported a positive association between cadmium levels and coronary heart disease, stroke and peripheral vascular disease. These associations were significant after adjusting for smoking status (<a href=\"#R15\" rid=\"R15\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591016\">15</a>). Similarly, Navas-Acien et al, studied the association between blood cadmium levels and PAD (<a href=\"#R6\" rid=\"R6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590997\">6</a>). The investigators reported a 2.9 fold increase in the prevalence of PAD when comparing the highest and lowest quartiles of blood cadmium levels.</p><p id=\"P10\" class=\"p p-last\">The toxic mechanism of cadmium is thought to be related to the inhibition of endothelial and calcium-calmodulin constitutive nitric oxide synthesis. Cadmium is also known to increase oxidative stress by being a catalyst in the formation of reactive oxygen species, increasing lipid peroxidation, and depleting glutathione and protein-bound sulfhydryl groups (<a href=\"#R6\" rid=\"R6\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591023\">6</a>).</p></div><div id=\"S5\" class=\"sec\"><h3>Other xenobiotic metals</h3><p id=\"P11\" class=\"p p-first-last\">In 2011, Agarwal and colleagues retrospectively studied the association of metals with cardiovascular and cerebrovascular disease (<a href=\"#R16\" rid=\"R16\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591017\">16</a>). Multivariable analyses found independent associations between the combined end point and increased levels of antimony, cadmium, cobalt and tungsten. This study is important, not only because it highlights the effect of cadmium on cardiovascular disease, but also because of the wide net it casts over other metals, implicating then in cardiovascular disease as well. And more to the point of this review, EDTA chelates these metals. EDTA does not, however chelate all metals associated with cardiovascular disease. It is a weak chelating agent for arsenic and does not effectively chelate mercury.</p></div><div id=\"S6\" class=\"sec\"><h3>Metals and diabetes mellitus</h3><p id=\"P12\" class=\"p p-first\">Diabetes mellitus is a well-known risk factor for developing early cardiovascular disease and mortality (<a href=\"#R17\" rid=\"R17\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590990\">17</a>). The evidence that xenobiotic metals are involved in the development of vascular complications of diabetes has two sources. Firstly, epidemiological evidence, recently reported, suggests that the vascular complications of arsenic and cadmium are more prominent in patients with diabetes (<a href=\"#R14\" rid=\"R14\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591004\">14</a>,<a href=\"#R18\" rid=\"R18\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_493054028\">18</a>).</p><p id=\"P13\">Secondly, metal-catalyzed oxygen chemistry is necessary for the non-enzymatic production of reactive oxygen species and formation of most advanced glycation end products (AGEs), advanced lipoxygenation end products (ALEs), and protein oxidation products. This is quite important, since the formation of these oxidation products, particularly AGEs, appears to be a plausible explanation for the development of complications of diabetes (<a href=\"#R19\" rid=\"R19\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591012\">19</a>,<a href=\"#R20\" rid=\"R20\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591011\">20</a>). Other transitional xenobiotic metals have also been found to be capable of catalyzing AGEs, and AGEs byproducts (<a href=\"#R21\" rid=\"R21\" class=\" bibr popnode\">21</a>,<a href=\"#R22\" rid=\"R22\" class=\" bibr popnode\">22</a>). During AGEs metabolism, the metals are neither discarded nor consumed. They continue to exist in cationic form, able to participate in subsequent reactions.</p><p id=\"P14\" class=\"p p-last\">The third line of evidence implicating metal chelation in the prevention of complications of diabetes stems from the little known finding that some medications commonly recognized as reducing complications of diabetes have been found to inhibit the Maillard reaction and the formation of AGEs via metal chelation (<a href=\"#R23\" rid=\"R23\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590994\">23</a>). Thus, in light of this basic and epidemiologic work, it is not surprising that metal chelation should show additional benefit in patients with diabetes.</p></div><div id=\"S7\" class=\"sec\"><h3>Chelation</h3><p id=\"P15\" class=\"p p-first\">When a molecule, either organic or inorganic, has the potential to form two or more stable bonds with a single metal atom, it is called a chelator, chelating agent or chelating ligand. This new complex is usually a non-ionic molecule, more stable, soluble, and resists dissociation. The word chelation comes directly from the Greek root <em>khele</em>, which means &#x0201c;claw&#x0201d;. This term accurately describes the claw like molecular structure and the enhanced metal affinity exhibited by chelating ligands when compared to other non-chelating molecules. A good example of an organic chelator is the porphyrin ring, which in turn, chelates the iron molecule and forms a chelate complex called the heme molecule. There are many organic and synthetic chelators.</p><p id=\"P16\" class=\"p p-last\">Many chelating ligands were synthetized specifically for binding certain metals. These compounds show enhanced chelating properties towards their targets. Important examples of synthetic chelators currently in use are dimercaprol (BAL), dimercaptosuccinic acid (DMSA), deferoxamine and various salts of ethylenediamine tetraacetic acid (EDTA). EDTA is a synthesized amino acid with strong, non-specific chelating properties for valences of +2 to +6. The EDTA-metal chelate is water soluble, and typically excreted in the urine. It can form strong covalent bonds with some xenobiotic metals, and increase the urinary excretion of calcium, zinc, cadmium and lead (<a href=\"#R24\" rid=\"R24\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591000\">24</a>). Its remarkable affinity to calcium led to the early hypothesis that EDTA might decalcify atherosclerotic plaque.</p></div><div id=\"S8\" class=\"sec\"><h3>Application of EDTA to treat atherosclerosis</h3><p id=\"P17\" class=\"p p-first\">In the 1950s, Clarke et al tested the effect of EDTA in a group of patients with severe angina, and found remarkable symptomatic and/or electrocardiographic improvement after repeated EDTA infusions in 17 out of 20 patients (<a href=\"#R25\" rid=\"R25\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591009\">25</a>). Following these observations, and despite the lack of well-powered clinical trials to evaluate its efficacy, the use of EDTA to treat angina and other forms of atherosclerotic disease continued to increase in the following 50 years after Clarke's initial report. This uncontrolled use led to many case reports and case series, some of them extensive, supporting EDTA chelation for cardiovascular disease. Unfortunately these case reports could, at best, be interpreted only as hypothesis generating.</p><p id=\"P18\">Three small, randomized studies, 2 in claudication (<a href=\"#R26\" rid=\"R26\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591014\">26</a>,<a href=\"#R27\" rid=\"R27\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591015\">27</a>) and one in angina (<a href=\"#R28\" rid=\"R28\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591021\">28</a>) encompassing 268 patients in aggregate tested the role of chelation therapy for atherosclerosis disease. Thus, these studies were probably underpowered to detect small to moderate clinical benefits of chelation therapy on the surrogate endpoint of exercise capacity, and none evaluated meaningful clinical endpoints such as cardiac events or mortality.</p><p id=\"P19\">These findings however, were interpreted by some authors as evidence against the efficacy of chelation therapy (<a href=\"#R29\" rid=\"R29\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591032\">29</a>). Yet the absence of evidence of efficacy did not constitute evidence of absence of chelation's efficacy. A small or moderate benefit of EDTA chelation could not be excluded (<a href=\"#R30\" rid=\"R30\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590993\">30</a>).</p><p id=\"P20\" class=\"p p-last\">In fact, a 2002 Cochrane systematic review on the role of chelation therapy in coronary heart disease concluded that the existing body of work on chelation therapy and coronary heart disease was insufficient to recommend for or against its use (<a href=\"#R31\" rid=\"R31\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590989\">31</a>). Nevertheless, in 2007 more than 100,000 adults in United States were using this form of therapy (<a href=\"#R32\" rid=\"R32\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590996\">32</a>), which could potentially cause severe hypocalcemia and death when misused (<a href=\"#R33\" rid=\"R33\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591003\">33</a>). It was in this context of uncertainty and in large, to respond to the public health question posed by EDTA chelation therapy, that the Trial to Assess Chelation Therapy (TACT) was born (<a href=\"#R34\" rid=\"R34\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591005\">34</a>). Thus, after nearly 50 years of empirical use of chelation therapy for atherosclerosis, TACT was the first randomized trial designed to evaluate the effects of an EDTA-based chelation regimen on clinical outcomes in patients with coronary disease.</p></div><div id=\"S9\" class=\"sec\"><h3>Overview of the TACT protocol</h3><p id=\"P21\" class=\"p p-first\">The TACT investigators were tasked with testing the most prevalent chelation treatment as used in the community. Thus, a 10-component solution (<a href=\"/pmc/articles/PMC4152775/table/T1/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\" co-legend-rid=\"\"><span>Table 1</span></a>) was now the standard. In addition, the EDTA-based chelation solution was also typically administered with high doses of oral multivitamins and multiminerals (MVM). In order to prevent confounding, and understand the interaction of the chelation solution with oral supplements, the trial was designed as a 2 &#x000d7; 2 factorial (<a href=\"#R34\" rid=\"R34\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590995\">34</a>). Patients were randomly assigned to 4 groups:</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T1\"><a href=\"/pmc/articles/PMC4152775/table/T1/\" target=\"table\" rid-ob=\"ob-T1\" rid-figpopup=\"T1\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table I\" title=\"Table I\" class=\"small-thumb\" src=\"/pmc/articles/PMC4152775/table/T1/?report=thumb\" src-large=\"/pmc/articles/PMC4152775/table/T1/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/table/T1/\" target=\"table\" rid-figpopup=\"T1\" rid-ob=\"ob-T1\">Table I</a></div><!--caption a4--><div><span><!--caption a8--><strong>Chelation Infusion Contents</strong></span></div></div></div><ol class=\"enumerated\" style=\"list-style-type:decimal\"><!--\nlist-behavior=enumerated\nprefix-word=\nmark-type=decimal\n--><li><div>Active intravenous (IV) chelation infusions + active oral MVM</div></li><li><div>Active IV chelation infusions + placebo oral MVM</div></li><li><div>Placebo IV chelation infusions + active oral MVM</div></li><li><div>Placebo IV chelation infusions + placebo oral MVM</div></li></ol><p id=\"P26\">Chelation-based infusions or placebo were administered 40 times: 30 weekly infusions, followed by 10 maintenance infusions 2 to 8 weeks apart. Oral high-dose MVM or oral placebo was administered throughout the course of the trial.</p><p id=\"P27\">Eligible patients were at least 50 years old, had experienced a myocardial infarction (MI) 6 weeks or more prior to enrollment, and had a serum creatinine of 2.0 mg/dL or less. The primary endpoint was a composite of death from any cause, reinfarction, stroke, coronary revascularization, or hospitalization for angina. The composite of cardiovascular death, reinfarction, or stroke was a prespecified secondary end point, as was quality of life. Treatment comparisons were performed according to the intention-to-treat principle and included all patients in the group to which they were randomized.</p><p id=\"P28\" class=\"p p-last\">The statistical plan originally called for 2372 patients to have 85% power to detect a 25% difference in the primary endpoint. During the course of enrollment it became clear that 1700 patients followed for a longer period was a more realistic goal. Thus, 1708 patients followed a median of 55 months maintained the same statistical power.</p></div><div id=\"S10\" class=\"sec\"><h3>Results of TACT &#x02013; overall population</h3><p id=\"P29\" class=\"p p-first\">The first patient was enrolled in September of 2003 and TACT was unblinded in August of 2012. 1708 patients were enrolled and randomized (839 patients to chelation, and 869 patients to placebo) at 134 sites, of which 81 (60%) were sites in which chelation therapy was already practiced. Patients received a total of 55,222 infusions. The median number of infusions received was 40 (IQR, 30-40); 76% of patients completed at least 30 infusions and 65% completed all 40 infusions. The median duration of follow-up was 55 (IQR, 26-60) months overall. Active treatment patients were followed up for 56 (IQR, 28-60) months and placebo patients were followed up for 53 (IQR, 24-60) months.</p><div id=\"S11\" class=\"sec sec-last\"><p></p><h4 class=\"inline\">TACT population </h4><p id=\"P30\" class=\"p p-first-last\">The median age was 65 (IQR, 59-72) years, 18% were women, 9% were minority, and the median body mass index was 30. The qualifying MI had occurred a median of 4.6 (IQR, 1.6-9.2) years prior to enrollment. The study population had a high prevalence of self-declared diabetes (31%), prior coronary revascularizations (83%), and high use of guideline-recommended medications such as aspirin (84%), P-blockers (72%), and statins (73%). Patients had a median fasting glucose level of 102 (IQR, 92-121) mg/dL and a low-density lipoprotein cholesterol (LDL-C) level of 89 (IQR, 67-115) mg/dL.</p></div></div><div id=\"S12\" class=\"sec\"><h3>Overview of publications</h3><p id=\"P31\" class=\"p p-first-last\">The initial TACT publication compared EDTA-based chelation with placebo infusions. Follow-up publications have reported on the oral MVM comparison, analysis of the 4 factorial groups, and an analysis of the subgroup of patients with diabetes (<a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>).</p><!--table ft1--><!--table-wrap mode=article t1--><div class=\"table-wrap iconblock ten_col whole_rhythm clearfix\" id=\"T2\"><a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"table\" rid-ob=\"ob-T2\" rid-figpopup=\"T2\" class=\"table img_link icnblk_img figpopup\"><img alt=\"Table II\" title=\"Table II\" class=\"small-thumb\" src=\"/pmc/articles/PMC4152775/table/T2/?report=thumb\" src-large=\"/pmc/articles/PMC4152775/table/T2/?report=previmg\" /></a><div class=\"icnblk_cntnt\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"table\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\">Table II</a></div><!--caption a4--><div><span>TACT summary of results.</span></div></div></div></div><div id=\"S13\" class=\"sec\"><h3>Comparison of chelation with placebo infusions</h3><p id=\"P32\" class=\"p p-first-last\">The primary end point occurred in 222 (26%) of the chelation group and 261 (30%) of the placebo group (<a href=\"#R35\" rid=\"R35\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591018\">35</a>). The Kaplan-Meier 5-year estimates for the primary end point were 32.8% (95% CI, 29.1% to 36.5%) in the chelation group and 38.5% (95% CI, 34.6% to 42.3%) in the placebo group (HR, 0.82; 95% CI, 0.69 to 0.99; P = .035) (<a href=\"/pmc/articles/PMC4152775/figure/F1/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\" co-legend-rid=\"lgnd_F1\"><span>Figure 1</span></a>). The 5-year number needed to treat (NNT) to prevent an event was 18. The statistical goal of the trial had been met. The effect of EDTA chelation on the components of the primary end point other than death was of similar magnitude as its overall effect. Finally, the event curves continued to separate after the infusions ended at about 14 months, suggesting the continued effect of chelating a metal toxin that might have taken a lifetime to accumulate. Chelation therapy reduced cardiovascular outcomes in a secondary prevention population.</p><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F1\" co-legend-rid=\"lgnd_F1\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4152775/figure/F1/\" target=\"figure\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\"><img src=\"/pmc/articles/PMC4152775/bin/nihms619516f1.gif\" class=\"small-thumb\" alt=\"Figure 1\" title=\"Figure 1\" src-large=\"/pmc/articles/PMC4152775/bin/nihms619516f1.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F1\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/figure/F1/\" target=\"figure\" rid-figpopup=\"F1\" rid-ob=\"ob-F1\">Figure 1</a></div><!--caption a4--><div><span>Kaplan-Meier Estimates of the Primary Composite End Point, EDTA Chelation Therapy vs placebo.</span></div></div></div></div><div id=\"S14\" class=\"sec\"><h3>Analysis of the 4 factorial groups</h3><p id=\"P33\" class=\"p p-first-last\">The analysis of the 4 factorial groups is particularly important because it evaluates chelation therapy as it is practiced in the community, and allows one to tease out the individual components (chelation, MVM, both, or neither) of benefit, if present. Overall, there was a stepwise reduction with the addition to double placebo of oral MVM, or chelation, or both. The 5-year Kaplan-Meier event rate estimate for the primary endpoint in the chelation + high-dose vitamin group was 31.9%, in the chelation + placebo vitamin group 33.7%, in the placebo infusion + active vitamin group 36.6%, and in the placebo infusions + placebo vitamin group 40.2 % (<a href=\"/pmc/articles/PMC4152775/figure/F2/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\" co-legend-rid=\"lgnd_F2\"><span>Figure 2</span></a>) (<a href=\"#R36\" rid=\"R36\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591007\">36</a>). The primary endpoint by treatment group occurred in 139 (32%) of the placebo infusion + placebo vitamin group, and 108 (26%) of patients in the chelation + high-dose vitamin group. The comparison of active infusion + active vitamins with placebo infusions + placebo vitamins was significant (HR 0.74, 95% CI (0.57 to 0.95; p=0.016, <a href=\"/pmc/articles/PMC4152775/figure/F2/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\" co-legend-rid=\"lgnd_F2\"><span>Figure 2</span></a>). The absolute difference in 5-year Kaplan-Meier estimated event rates between placebo-placebo and active-active groups was 8.3% and the number needed to treat (NNT) to prevent 1 event over 5 years was 12 (<a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>). Thus, EDTA chelation plus MVM on a background of optimal medical therapy offered important benefits when compared to optimal medical therapy, including statins, alone.</p><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F2\" co-legend-rid=\"lgnd_F2\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4152775/figure/F2/\" target=\"figure\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\"><img src=\"/pmc/articles/PMC4152775/bin/nihms619516f2.gif\" class=\"small-thumb\" alt=\"Figure 2\" title=\"Figure 2\" src-large=\"/pmc/articles/PMC4152775/bin/nihms619516f2.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F2\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/figure/F2/\" target=\"figure\" rid-figpopup=\"F2\" rid-ob=\"ob-F2\">Figure 2</a></div><!--caption a4--><div><span>5-year Kaplan-Meier Event Rate Estimates for the Primary Composite Endpoint for the Four Factorial Groups.</span></div></div></div></div><div id=\"S15\" class=\"sec\"><h3>Analysis of patients with diabetes</h3><p id=\"P34\" class=\"p p-first-last\">Diabetes mellitus was prespecified as a subgroup for analysis in TACT. A total of 633 (37%) patients enrolled in the study met the definition of diabetes mellitus. Treatment with EDTA infusions reduced the primary end point (EDTA chelation vs. placebo: 25% vs. 38%; HR 0.59; 95% CI 0.44 &#x02013; 0.79; p&#x0003c;0.0002) (<a href=\"#R37\" rid=\"R37\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591006\">37</a>). The Kaplan-Meier curves again continued to diverge after the infusions stopped, indirectly supporting the metal-chelation hypothesis. There was a 15% absolute decrease in the 5-year Kaplan Meier primary event rate (<a href=\"/pmc/articles/PMC4152775/figure/F3/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\" co-legend-rid=\"lgnd_F3\"><span>Figure 3</span></a>)_and a 41% relative reduction in risk. The 5 year NNT was 6.5 (95% CI, 4.4 &#x02013; 12.7) (<a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>). There were important and consistent reductions in the components of the primary endpoint as well. Rates of the principal secondary endpoint, cardiovascular death, MI, or stroke were also lower for diabetic patients randomized to EDTA chelation (HR, 0.60; 95% CI, 0.39&#x02013;0.91; P=0.017), with a 5.1% absolute decrease in the 5-year Kaplan&#x02013;Meier event rate and a relative reduction of 40%. Patients with diabetes mellitus randomized to EDTA chelation had a significant reduction in recurrent MI (HR, 0.48; 95% CI, 0.26&#x02013;0.88; P=0.015), in all-cause mortality (HR, 0.57; 95% CI, 0.36&#x02013;0.88; P=0.011; <a href=\"/pmc/articles/PMC4152775/figure/F4/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\" co-legend-rid=\"lgnd_F4\"><span>Figure 4</span></a>; 5-year NNT= 12; <a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>), and in coronary revascularizations (HR, 0.68; 95% CI, 0.47&#x02013;0.99; P=0.042). Furthermore, when the factorial analyses comparing chelation + active vitamins with placebo infusions + placebo oral vitamins, the primary endpoint occurred in 56 (38%) of the placebo infusion + placebo vitamin group, and 36 (23%) of patients in the chelation + high-dose vitamin group (HR 0.49, 95% CI (0.33, 0.75) p&#x0003c;0.001, <a href=\"/pmc/articles/PMC4152775/figure/F5/\" target=\"figure\" class=\"fig-table-link fig figpopup\" rid-figpopup=\"F5\" rid-ob=\"ob-F5\" co-legend-rid=\"lgnd_F5\"><span>Figure 5</span></a>), with a 5-year NNT=5.5 (<a href=\"/pmc/articles/PMC4152775/table/T2/\" target=\"true\" class=\"fig-table-link table figpopup\" rid-figpopup=\"T2\" rid-ob=\"ob-T2\" co-legend-rid=\"\"><span>Table 2</span></a>) (<a href=\"#R36\" rid=\"R36\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398590992\">36</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F3\" co-legend-rid=\"lgnd_F3\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4152775/figure/F3/\" target=\"figure\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\"><img src=\"/pmc/articles/PMC4152775/bin/nihms619516f3.gif\" class=\"small-thumb\" alt=\"Figure 3\" title=\"Figure 3\" src-large=\"/pmc/articles/PMC4152775/bin/nihms619516f3.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F3\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/figure/F3/\" target=\"figure\" rid-figpopup=\"F3\" rid-ob=\"ob-F3\">Figure 3</a></div><!--caption a4--><div><span><strong>TACT</strong> Kaplan-Meier Estimates of the Primary Composite Endpoint EDTA Chelation Therapy vs. Placebo Subset of Patients with Diabetes: Hx, Med Use or Baseline Glucose&#x0003e;=126</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F4\" co-legend-rid=\"lgnd_F4\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4152775/figure/F4/\" target=\"figure\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\"><img src=\"/pmc/articles/PMC4152775/bin/nihms619516f4.gif\" class=\"small-thumb\" alt=\"Figure 4\" title=\"Figure 4\" src-large=\"/pmc/articles/PMC4152775/bin/nihms619516f4.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F4\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/figure/F4/\" target=\"figure\" rid-figpopup=\"F4\" rid-ob=\"ob-F4\">Figure 4</a></div><!--caption a4--><div><span><strong>TACT</strong> Kaplan-Meier Estimates of Death EDTA Chelation Therapy vs. Placebo Subset of Patients with Diabetes: Hx, Med Use or Basefine Glucose&#x0003e;=126</span></div></div></div><!--fig ft0--><!--fig mode=article f1--><div class=\"fig iconblock ten_col whole_rhythm clearfix\" id=\"F5\" co-legend-rid=\"lgnd_F5\"><a class=\"icnblk_img figpopup\" href=\"/pmc/articles/PMC4152775/figure/F5/\" target=\"figure\" rid-figpopup=\"F5\" rid-ob=\"ob-F5\"><img src=\"/pmc/articles/PMC4152775/bin/nihms619516f5.gif\" class=\"small-thumb\" alt=\"Figure 5\" title=\"Figure 5\" src-large=\"/pmc/articles/PMC4152775/bin/nihms619516f5.jpg\" /></a><div class=\"icnblk_cntnt\" id=\"lgnd_F5\"><div><a class=\"figpopup\" href=\"/pmc/articles/PMC4152775/figure/F5/\" target=\"figure\" rid-figpopup=\"F5\" rid-ob=\"ob-F5\">Figure 5</a></div><!--caption a4--><div><span>5-year Kaplan-Meier Event Rate Estimates for the Primary Composite Endpoint in Diabetic Patients. Active-active vs. Placebo-placebo</span></div></div></div></div><div id=\"S16\" class=\"sec\"><h3>Safety of chelation therapy</h3><p id=\"P35\" class=\"p p-first-last\">TACT also showed that, as used in the trial, treatment with EDTA was safe. EDTA was associated with few side effects and there were no differences in serious adverse events compared with placebo. Hypocalcemia, defined as a calcium level less than 8.5 mg/dL prior to an infusion, was reported in 52 chelation patients (6.2%) and 30 placebo patients (3.5%) (P=0.008). One patient had symptomatic hypocalcemia associated with muscle cramping that led to an emergency department visit.</p></div><div id=\"S17\" class=\"sec\"><h3>TACT in context</h3><p id=\"P36\" class=\"p p-first\">TACT is a unique trial that crossed rigid lines of scientific thought. Its scientific basis is decades deep. The association of metals with cardiovascular disease is not new. And neither is the participation of metal-catalyzed oxygen chemistry in the production of AGEs. But this knowledge has been held in silos - in environmental health, epidemiology, and diabetes basic science&#x02013; silos the cardiologist does not often visit. Thus, TACT served as a logical clinical test of these lines of knowledge. As such, the results have unveiled an exciting area of new cardiovascular research with the underlying concept that xenobiotic metals may be a modifiable risk factor for cardiovascular disease. Despite the epidemiological association between xenobiotic metals and cardiovascular disease, and the presumed effect of EDTA removing these toxins; the exact mechanism of how chelation reduced major cardiovascular events, is still unknown. Indeed, the positive effect of high doses of vitamin C on vascular endothelium should not be neglected as a potential contributing agent.</p><p id=\"P37\" class=\"p p-last\">The TACT results, also, must be placed in context. In a 2006 review of statin therapy (<a href=\"#R38\" rid=\"R38\" class=\" bibr popnode tag_hotlink tag_tooltip\" id=\"__tag_398591001\">38</a>), the 5.1 year NNT for major cardiovascular events in a secondary prevention population, an endpoint similar to TACT, was 16. For chelation + oral vitamins it was 12. Even more striking is the effect on patients with diabetes. The 5.1 year NNT for major coronary events for statins was 17, for the TACT infusion treatment alone, 6.5 (5-year NNT).</p></div><div id=\"S18\" class=\"sec\"><h3>Conclusions</h3><p id=\"P38\" class=\"p p-first-last\">Among patients with a prior MI, a regimen of 40 infusions of disodium EDTA-based infusions safely reduced cardiovascular events in a post-MI population, suggesting that xenobiotic metal pollutants are cardiovascular risk factors. The effect of the chelation infusions was enhanced with high doses of oral multivitamins and multiminerals. The therapeutic benefit was particularly striking in diabetic patients. These results were observed against a background of modern evidence-based post-MI therapy.</p></div><div id=\"S19\" class=\"sec sec-last\"><h3>Future research</h3><p id=\"P39\" class=\"p p-first-last\">At present, the unique nature of these findings demands followup research to replicate findings and understand mechanisms. Such research should take place in patients with diabetes and macrovascular disease, including peripheral artery disease. The xenobiotic metal hypothesis that we have described should be tested, as should the development of AGEs and RAGE activation. Additionally, pragmatic, patient oriented outcome trials, comparing traditional treatment of severe PAD with standard care plus chelation could be carried out. Because of the generic nature of this intervention, there is absolutely no pharmaceutical company interest in this therapy, so all of us await NIH initiatives. Still, the magnitude of benefit was such that it suggests urgency in replication and implementation, which should, due the excellent safety record, occur simultaneously.</p></div></div><div id=\"__fn-groupid497187\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__fn-groupid497187title\">Footnotes</h2><!--back/fn-group--><div class=\"fm-sec half_rhythm small\"><p class=\"fn sec\" id=\"FN2\"> <p id=\"__p1\" class=\"p p-first-last\">Disclosures: There are no conflicts of interest.</p></p><p class=\"fn sec\" id=\"FN3\"><p id=\"__p2\" class=\"p p-first-last\"><strong>Publisher's Disclaimer: </strong>This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</p></p></div></div><div id=\"__ref-listid497213\" class=\"tsec sec\"><h2 class=\"head no_bottom_margin\" id=\"__ref-listid497213title\">References</h2><div class=\"ref-list-sec sec\" id=\"reference-list\"><div class=\"ref-cit-blk half_rhythm\" id=\"R1\">1. <span class=\"element-citation\">Agency for Toxic Substances and Disease Registry (ATSDR) <span class=\"ref-journal\">The priority list of hazardous substances.</span> Atlanta (GA): U. S. Department of Health of Human Services, Public Health Service; 2011. </span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R2\">2. <span class=\"element-citation\">Nordberg GF, Nogawa K, Nordberg MFL.  Cadmium. In: Nordberg GF, Fowler BA, Nordberg MFL, editors. <span class=\"ref-journal\">Handbook on the Toxicology of Metals.</span> Third. Elsevier; 2007. pp. 445\u201386.</span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R3\">3. <span class=\"element-citation\">Pirkle JL, Schwartz JE, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. <span><span class=\"ref-journal\">Am J Epidemiol. </span>1985;<span class=\"ref-vol\">121</span>:246\u201358.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/4014119\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R4\">4. <span class=\"element-citation\">Nawrot T, Thijs L, Den Hond E, Roels H, Staessen J. An epidemiological reappraisal of the association between blood pressure and blood lead: a metaanalysis. <span><span class=\"ref-journal\">J Hum Hypertens. </span>2002;<span class=\"ref-vol\">16</span>:123\u201331.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11850770\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R5\">5. <span class=\"element-citation\">Menke A, Muntner P, Batuman V, Silbergeld EK, Guallar E. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. <span><span class=\"ref-journal\">Circulation. </span>2006 Sep 26;<span class=\"ref-vol\">114</span>(13):1388\u201394.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16982939\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R6\">6. <span class=\"element-citation\">Navas-Acien A, Selvin E, Sharrett AR, Calderon-Aranda E, Silbergeld E, Guallar E. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. <span><span class=\"ref-journal\">Circulation. </span>2004 Jun 29;<span class=\"ref-vol\">109</span>(25):3196\u2013201.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/15184277\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R7\">7. <span class=\"element-citation\">Lustberg M, Silbergeld E. Blood lead levels and mortality. <span><span class=\"ref-journal\">Arch Intern Med. </span>2002;<span class=\"ref-vol\">162</span>:2443\u20139.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12437403\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R8\">8. <span class=\"element-citation\">Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES) <span><span class=\"ref-journal\">Environ Health Perspect. </span>2008;<span class=\"ref-vol\">116</span>:51\u20136.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2199293/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/18197299\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R9\">9. <span class=\"element-citation\">Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. <span><span class=\"ref-journal\">Free Radical Biology and Medicine. </span>1995:321\u201336.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/7744317\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R10\">10. <span class=\"element-citation\">Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of lead-induced hypertension. <span><span class=\"ref-journal\">Hypertension. </span>1999;<span class=\"ref-vol\">34</span>:558\u201362.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/10523326\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R11\">11. <span class=\"element-citation\">Wagner GJ, Yeargan R. Variation in cadmium accumulation potential and tissue distribution of cadmium in tobacco. <span><span class=\"ref-journal\">Plant Physiol. </span>1986;<span class=\"ref-vol\">82</span>:274\u20139.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC1056102/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16665005\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R12\">12. <span class=\"element-citation\">J&#x000e4;rup L, Berglund M, Elinder CG, Nordberg G, Vahter M. Health effects of cadmium exposure--a review of the literature and a risk estimate. <span><span class=\"ref-journal\">Scand J Work Environ Health. </span>1998;<span class=\"ref-vol\">24</span>(Suppl 1):1\u201351.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/9569444\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R13\">13. <span class=\"element-citation\">Tellez-Plaza M, Navas-Acien A, Menke A, Crainiceanu CM, Pastor-Barriuso R, Guallar E. Cadmium Exposure and All-Cause and Cardiovascular Mortality in the U. S. General Population. <span><span class=\"ref-journal\">Environ Health Perspect. </span>2012 Jul;<span class=\"ref-vol\">120</span>(7):1017\u201322.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3404657/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22472185\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R14\">14. <span class=\"element-citation\">Tellez-Plaza M, Guallar E, Howard BV, Umans JG, Francesconi Ka, Goessler W, et al.  Cadmium exposure and incident cardiovascular disease. <span><span class=\"ref-journal\">Epidemiology. </span>2013;<span class=\"ref-vol\">24</span>:421\u20139.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4142588/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23514838\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R15\">15. <span class=\"element-citation\">Tellez-Plaza M, Jones MR, Dominguez-Lucas A, Guallar E, Navas-Acien A. Cadmium exposure and clinical cardiovascular disease: a systematic review. <span><span class=\"ref-journal\">Curr Atheroscler Rep. </span>2013;<span class=\"ref-vol\">15</span>:356.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3858820/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23955722\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R16\">16. <span class=\"element-citation\">Agarwal S, Zaman T, Tuzcu EM, Kapadia SR. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. <span><span class=\"ref-journal\">Angiology. </span>2011 Jul;<span class=\"ref-vol\">62</span>(5):422\u20139.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21421632\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R17\">17. <span class=\"element-citation\">The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. <span><span class=\"ref-journal\">Lancet. </span>2010;<span class=\"ref-vol\">375</span>:2215\u201322.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC2904878/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/20609967\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R18\">18. <span class=\"element-citation\">Moon KA, Guallar E, Umans JG, Devereux RB, Best LG, Francesconi KA, et al.  Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. <span><span class=\"ref-journal\">Ann Intern Med. </span>2013;<span class=\"ref-vol\">159</span>:649\u201359.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4157936/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24061511\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R19\">19. <span class=\"element-citation\">Yamagishi S, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. <span><span class=\"ref-journal\">Biochim Biophys Acta Elsevier BV. </span>2012 May;<span class=\"ref-vol\">1820</span>(5):663\u201371.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/21440603\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R20\">20. <span class=\"element-citation\">Manigrasso MB, Juranek J, Ramasamy R, Schmidt AM. Unlocking the biology of RAGE in diabetic microvascular complications. <span><span class=\"ref-journal\">Trends in Endocrinology and Metabolism. </span>2014:15\u201322.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3877224/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24011512\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R21\">21. <span class=\"element-citation\">Suhartono E, Triawanti T, Leksono AS, Djati MS. The Role of Cadmium in Proteins Glycation by Glucose: Formation of Methylglyoxal and Hydrogen Peroxide in Vitro. <span><span class=\"ref-journal\">J Med Bioeng. </span>2014;<span class=\"ref-vol\">3</span>(1):59\u201362.</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R22\">22. <span class=\"element-citation\">Husna aH, Ramadhani Ea, ED T, Yulita aF, Suhartono E. The Role Formation of Methylglyoxal, Carbonyl Compound, Hydrogen Peroxide and Advance Oxidation Protein Product Induced Cadmium in Ovarian Rat. <span><span class=\"ref-journal\">Int J Chem Eng Appl. </span>2014 Aug;<span class=\"ref-vol\">5</span>(4):319\u201323.</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R23\">23. <span class=\"element-citation\">Nagai R, Murray DB, Metz TO, Baynes JW. Chelation: A Fundamental Mechanism of Action of AGE Inhibitors, AGE Breakers, and Other Inhibitors of Diabetes Complications. <span><span class=\"ref-journal\">Diabetes. </span>2012:549\u201359.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3282805/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22354928\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R24\">24. <span class=\"element-citation\">Waters RS, Bryden Na, Patterson KY, Veillon C, Anderson RA. EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. <span><span class=\"ref-journal\">Biol Trace Elem Res. </span>2001 Dec;<span class=\"ref-vol\">83</span>(3):207\u201321.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11794513\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R25\">25. <span class=\"element-citation\">Clarke CN, Clarke NE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. <span><span class=\"ref-journal\">Am J Med Sci. </span>1956;<span class=\"ref-vol\">6</span>(232):654\u201366.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/13372537\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R26\">26. <span class=\"element-citation\">Guldager B, Jelnes R, J&#x000f8;rgensen SJ, Nielsen JS, Klaerke A, Mogensen K, et al.  EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study. <span><span class=\"ref-journal\">Journal of internal medicine. </span>1992 Mar;:261\u20137.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/1556523\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R27\">27. <span class=\"element-citation\">Van Rij AM, Solomon C, Packer SG, Hopkins WG. Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. <span><span class=\"ref-journal\">Circulation. </span>1994:1194\u20139.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/8087928\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R28\">28. <span class=\"element-citation\">Knudtson ML, Wyse DG, Galbraith PD, Brant R, Hildebrand K, Paterson D, et al.  Chelation therapy for ischemic heart disease: a randomized controlled trial. <span><span class=\"ref-journal\">JAMA. </span>2002;<span class=\"ref-vol\">287</span>:481\u20136.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/11798370\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R29\">29. <span class=\"element-citation\">Ernst E. Chelation therapy for coronary heart disease: An overview of all clinical investigations. <span><span class=\"ref-journal\">Am Heart J. </span>2000;<span class=\"ref-vol\">140</span>:139\u201341.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/10874275\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R30\">30. <span class=\"element-citation\">Lamas Ga, Ackermann A. Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? <span><span class=\"ref-journal\">Am Heart J. </span>2000 Jul;<span class=\"ref-vol\">140</span>(1):4\u20135.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/10874253\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R31\">31. <span class=\"element-citation\">Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. <span><span class=\"ref-journal\">Cochrane Database Syst Rev. </span>2002:CD002785.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/12519577\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R32\">32. <span class=\"element-citation\">Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. <span><span class=\"ref-journal\">Natl Health Stat Report. </span>2008:1\u201323.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/19361005\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R33\">33. <span class=\"element-citation\">Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. <span><span class=\"ref-journal\">MMWR Morb Mortal Wkly Rep. </span>2006 Mar 3;<span class=\"ref-vol\">55</span>(8):204\u20137.</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16511441\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R34\">34. <span class=\"element-citation\">Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, et al.  Design of the Trial to Assess Chelation Therapy (TACT) <span><span class=\"ref-journal\">Am Heart J Mosby, Inc. </span>2012 Jan;<span class=\"ref-vol\">163</span>(1):7\u201312.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC3243954/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/22172430\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R35\">35. <span class=\"element-citation\">Lamas Gervasio A, MD, Goertz Christine, DC, PhD, Boineau Robin, MD, MA, Mark Daniel B, MD, MPH, Rozema Theodore, MD, Nahin Richard L, PhD, MPH, et al.  for the TI. Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients With Previous Myocardial Infarction: The TACT Randomized Trial. <span><span class=\"ref-journal\">JAMA. </span>2013;<span class=\"ref-vol\">309</span>:1241.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4066975/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/23532240\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R36\">36. <span class=\"element-citation\">Lamas GA, Boineau R, Goertz C, Mark DB, Rosenberg Y, Stylianou M, et al.  EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. <span><span class=\"ref-journal\">Am Heart J. </span>2014 Apr;</span> Internet. [cited 2014 Jun 5]; Available from:  <a href=\"http://dx.doi.org/10.1016/j.ahj.2014.02.012\" ref=\"reftype=extlink&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI&amp;rendering-type=normal\" target=\"pmc_ext\">http://dx.doi.org/10.1016/j.ahj.2014.02.012</a>. <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4069605/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24952858\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R37\">37. <span class=\"element-citation\">Escolar E, Lamas Ga, Mark DB, Boineau R, Goertz C, Rosenberg Y, et al.  The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT) <span><span class=\"ref-journal\">Circ Cardiovasc Qual Outcomes. </span>2014 Jan;<span class=\"ref-vol\">7</span>(1):15\u201324.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC4111470/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/24254885\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div><div class=\"ref-cit-blk half_rhythm\" id=\"R38\">38. <span class=\"element-citation\">Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. <span><span class=\"ref-journal\">BMJ. </span>2006;<span class=\"ref-vol\">332</span>:1115\u201324.</span> <span class=\"nowrap ref pmc\">[<a class=\"int-reflink\" href=\"/pmc/articles/PMC1459619/\">PMC free article</a>]</span>  <span class=\"nowrap ref pubmed\">[<a href=\"/pubmed/16585050\" target=\"pmc_ext\" ref=\"reftype=pubmed&amp;article-id=4152775&amp;issue-id=242292&amp;journal-id=319&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal\">PubMed</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id=\"rightcolumn\" class=\"four_col col last\">\n        <!-- Custom content above discovery portlets -->\n        <div class=\"col6\">\n            \n        </div>\n        \n        <div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\"><div class=\"format-menu\"><h2>Formats:</h2><ul><li class=\"selected\">Article</li> | <li><a href=\"/pmc/articles/PMC4152775/?report=reader\">PubReader</a></li> | <li class=\"epub-link\"><a href=\"/pmc/articles/PMC4152775/epub/\">ePub (beta)</a></li> | <li><a href=\"/pmc/articles/PMC4152775/pdf/nihms619516.pdf\">PDF (343K)</a></li> | <li><a href=\"#\" data-citationid=\"PMC4152775\" class=\"citationexporter ctxp\">Citation</a></li></ul></div></div><div xmlns:np=\"http://ncbi.gov/portal/XSLT/namespace\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" class=\"share-buttons\"><h2>Share</h2><ul><li class=\"facebook\"><a href=\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4152775%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047626\" alt=\"Share on Facebook\" />\n                             Facebook\n                        </a></li><li class=\"twitter\"><a href=\"https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4152775%2F&amp;text=Chelation%20Therapy%20and%20Cardiovascular%20Disease%3A%20Connecting%20Scientific%20Silos%20to%20Benefit%20Cardiac%20Patients\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047627\" alt=\"Share on Twitter\" />\n                             Twitter\n                        </a></li><li class=\"gplus\"><a href=\"https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4152775%2F\"><img src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/img/4047628\" alt=\"Share on Google Plus\" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id=\"ajax-portlets\" data-pmid=\"25106084\" data-aiid=\"4152775\" data-aid=\"4152775\" data-iid=\"242292\" data-domainid=\"319\" data-domain=\"nihpa\" data-accid=\"PMC4152775\" data-md5=\"6353fa4b0f2a0ff1727bfe47be909ebd\"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class=\"col7\">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class=\"col8\">\n    \n</div>\n<div class=\"col9\">\n    \n</div>\n\n<script src=\"/corehtml/pmc/js/jquery.scrollTo-1.4.2.js\"></script>\n<script>\n    (function($){\n        $('.skiplink').each(function(i, item){\n            var href = $($(item).attr('href'));\n            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus\n            $(item).on('click', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id=\"body-link-poppers\"></div>\n                        </div>\n                        <div class=\"bottom\">\n                            \n                            <div id=\"NCBIFooter_dynamic\">\n    <div class=\"breadcrumbs\">You are here: \n            <span id=\"breadcrumb_text\"><a href=\"/guide/\">NCBI</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/guide/literature/\">Literature</a> &gt; <a href=\"https://www.ncbi.nlm.nih.gov/pmc/\">PubMed Central (PMC)</a></span></div>\n    <a id=\"help-desk-link\" class=\"help_desk jig-ncbihelpwindow\" target=\"_blank\" href=\"/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.39&amp;Time=2016-11-05T22:45:43-04:00&amp;Host=ptpmc202\">Write to the Help Desk</a>\n    \n</div>\n\n                            <div class=\"footer\" id=\"footer\">\n    \n    <div class=\"subfooter\"> </div><script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/preloaderWidget.js\"> </script>\n    <div id=\"external-disclaimer\" class=\"offscreen_noflow\">\n        External link. Please review our <a href=\"https://www.nlm.nih.gov/privacy.html\">privacy policy</a>.\n    </div>    \n    <div id=\"ncbifooter\" class=\"contact_info\">      \n        <div id=\"footer-contents-right\">\n            <div id=\"nlm_thumb_logo\">\n                <a href=\"https://www.nlm.nih.gov\" title=\"NLM\">NLM</a>\n            </div>\n            <div id=\"nih_thumb_logo\">\n                <a href=\"https://www.nih.gov\" title=\"NIH\">NIH</a>\n            </div>\n            <div id=\"hhs_thumb_logo\">\n                <a href=\"https://www.hhs.gov\" title=\"DHHS\">DHHS</a>\n            </div>\n            <div id=\"usagov_thumb_logo\">\n                <a href=\"https://www.usa.gov\" title=\"USA.gov\">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id=\"footer-contents-left\">\n            <p class=\"address vcard\">\n                <span class=\"url\">\n                    <a class=\"fn url newdomain\" href=\"https://www.ncbi.nlm.nih.gov\">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class=\"org url newdomain\"><a href=\"https://www.nlm.nih.gov/\">U.S. National Library of Medicine</a></span>\n                <span class=\"adr\">\n                    <span class=\"street-address\">8600 Rockville Pike</span>, <span class=\"locality\">Bethesda</span>\n                    <span class=\"region\">MD</span>, <span class=\"postal-code\">20894</span>\n                    <span class=\"country-name\">USA</span>\n                </span>\n            </p>\n            \n            <a href=\"/home/about/policies.shtml\">Policies and Guidelines</a> | <a href=\"/home/about/contact.shtml\">Contact</a>\n        </div>\n    </div>\n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1\"> </script>    \n    <script type=\"text/javascript\" src=\"/portal/portal3rc.fcgi/static/js/hfjs2.js\"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class=\"PAFAppResources\"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt=\"statistics\" src=\"/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=nihpa&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC4152775/&amp;ncbi_app=pmc\" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id=\"PageFixtures\" label=\"styles\"></component>-->\n    \n\n<!-- F4FC52E181E99561_0128SID /projects/PMC/PMCViewer@4.39 ptpmc202 v4.1.r508797 Mon, Aug 01 2016 12:51:16 -->\n\n<script type=\"text/javascript\" src=\"//static.pubmed.gov/portal/portal3rc.fcgi/4132802/js/3879255/4121861/3818874/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js\" snapshot=\"pmc\"></script></body>\n</html>"}